Leukemia presentation is reported in peripheral T cell lymphoma patients, this is not the case with ALCL. 4 Bone marrow involvement is seen in only 20% of ALCL cases; the majority of these patients are ALK1 positive. Liver enlargement is seen in 17% of ALK1 positive patients; but in none of the 43 ALK1-positive cases was involvement of the spleen noted.
Discordant expression of AC133 and AC141 in patients with myelodysplastic syndrome (MDS) and acute myelogeneous leukemia (AML)
TO THE EDITOR Yin et al 1 described a monoclonal antibody (MAB), AC133, that is reactive with an epitope on the extracellular domain of a newly recognized five-transmembrane protein expressed on CD34
+ early hematopoietic precursors. A second MAB, AC141, has become available which recognizes the same antigen as AC133 but a different epitope. 2 Miraglia et al 2 cloned the gene and showed that this gene product was also expressed on a subset of leukemia cells. Horn et al 3 presented data on 30 patients with acute myeloid leukemia, 24 of whom expressed AC133, bright in nine and dim in 15. It was of note that dim AC133 staining was also seen on CD34 − leukemia cells in five patients. We described aberrant antigen expression on blast cells in patients with AML 4 and more recently in patients with myelodysplastic syndrome (MDS). 5 We speculated that dysregulation of antigen expression in those patients may affect the antigen recognized by MABs AC133, AC141, as well as CD34.
Bone marrow aspirates (n = 3) and peripheral blood stem cell samples (n = 13), including one preparation enriched for CD34 + precursors, were obtained from normal transplant donors. Peripheral blood samples and marrow aspirates were obtained from 14 patients with AML who were not in remission, and from 16 patients with MDS (refractory anemia (RA), RA with excess blasts (RAEB) or RAEB in transformation (RAEB-T)). Samples were processed and analyzed by multidimensional flow cytometry as described. 4 MABs used in the analysis included FITC-conjugated anti-CD34 (CD34 FITC), PerCPconjugated anti-CD45 (CD45 PerCP) (both purchased from Becton Dickinson (San José, CA, USA), and AC133PE and AC141PE (Amcell Corporation, Sunnyvale, CA, USA). A second staining step using biotin-conjugated AC133 or AC141 (Amcell Corporation) and streptavidin APC (Pharmingen, San Diego, CA, USA) was added to allow for four-color analysis.
As previously described in patients with AML, 3 AC133 was expressed on 25 of 30 samples, while CD34 was expressed on 28 of 30 marrows. Most interesting was the discordance in the intensity of expression of AC133 and AC141 in patients with AML or MDS. Precursor cells from normal marrow or peripheral blood stem cells showed a consistent staining pattern with respect to the two epitopes recognized by AC133 (bright) and AC141 (intermediate) and CD34 expression (bright) ( Figure 1A) . The relationship in the expression between these epitopes was most readily shown in four-color analysis with the gate set on blast cells (CD45 dim, decreased right angle light scatter, CD34 + ). 6 The correlation between AC133 and AC141
Figure 1
Expression of AC133, AC141 and CD34 using three-and four-color flow cytometric analysis. Precursor cells from a PBSC product obtained from a normal donor exhibit normal expression and intensity relationships between these three antigens (A). Discordant expression between AC133 and AC141 is seen in samples from patients with AML (B) and MDS (C). Of note is the subpopulation of normal staining CD34 + blasts (circled) present in the marrow of patient B.
remained the same, regardless of the fluorescence probe used. In patients with both AML and MDS, an aberrant phenotype including a discordant pattern of the intensity of antigen expression of AC133 and AC141 was observed in 16 of 30 samples (53%), including 10 of 14 AML (71%), and six of 16 MDS samples (38%) (Figure 1B and C). In addition, three of 30 marrow samples showed an aberrant relationship between the expression of CD34 and AC133 or AC141, respectively.
As both MABs recognize epitopes on the same gene product, it was expected that AC133 and AC141 would recognize cells in a concordant pattern. Conceivably, discordant staining of AML or MDS blasts by MABs AC133 and AC141 could serve as a marker for the malignant clone. The reason for differences in the recognition of the same antigen by these two antibodies is unclear. The epitopes recognized by both MABs are glycosylated. Glycosylation is a post-translational event which can be altered in cells that have undergone malignant transformation. 7 One might speculate that alterations in glycosylation may also affect the adherence of cells which in turn may lead to abnormal localization of immature precursors (ALIP) in the marrow as described for patients with MDS. 8 Further studies will have to show whether the discordantly recognized cell population corresponds to those cells that also contain chromosomal or molecular clonal markers. If so, double staining with AC133 and AC141 might be useful to recognize and to eliminate the clonal cell population from MDS marrow and purge it for autologous stem cell transplantation. Such an Leukemia approach would also facilitate the analysis of subpopulations of precursor cells for signals that are thought to be involved in programmed cell death in the marrow. 
